Eterna Therapeutics Inc
ERNA
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.92M
Close$
$5.53
154.6% upside
Current Fair Value
154.6% upsideUndervalued by 154.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.92 Million |
|---|---|
| Enterprise Value | $-761,214.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-56 |
| Beta | 2.65 |
| Outstanding Shares | 1,183,000 |
Return
| Return on Equity | -383.28% |
|---|---|
| Return on Assets | -194.22% |
| Return on Invested Capital | -323.59% |
Valuation & Multiples
| P/E Ratio | -0.13 |
|---|---|
| PEG | -0.46 |
| Price to Sales | - |
| Price to Book Ratio | 1.09 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.07 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.46 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-3.30
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
$-3.84
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.00%▼ 15.05% |
|---|---|
| Total Invested | $236,242▼ 66.79% |
| Investors Holding | 9▼ 10.00% |
ESG Score
No data
About Eterna Therapeutics Inc
2,018 employees
CEO: Sanjeev Luther Operating in the preclinical phase, Ernexa Therapeutics Inc. is dedicated to advancing therapies based on induced mesenchymal stem cells (iMSC) to combat both solid tumors and autoimmune conditions. Its primary therapeutic, ERNA-101, is ...